News | Ablation Systems | May 16, 2019

CardioFocus Announces Results From HeartLight X3 Ablation System Pivotal Study

Study results presented at the Heart Rhythm Society's 40th Annual Scientific Sessions

CardioFocus Announces Results From HeartLight X3 Ablation System Pivotal Study

May 16, 2019 — CardioFocus Inc. announced the presentation of results from its pivotal confirmatory study evaluating the HeartLight X3 System for the treatment of atrial fibrillation (AFib). The results, which demonstrated superior procedural times and impressive procedural outcomes, according to the company, were presented during the Heart Rhythm Society's (HRS) 40th Annual Scientific Sessions, May 8-11, 2019 in San Francisco.

Petr Neužil, M.D., Ph.D., head of the Department of Cardiology at Na Homolce Hospital (NHH) in Prague, Czech Republic, and the trial's lead investigator, outlined the findings during a presentation titled, "Performance of a 3rd Generation Visually-Guided Laser Balloon for Pulmonary Vein Isolation: Results of the X3 Study." In the evaluation of 60 patients, the HeartLight X3 System consistently achieved very rapid pulmonary vein isolation (PVI), in as few as three minutes for a single vein.

The HeartLight X3 System is a third-generation AFib ablation technology building upon the features of the HeartLight Endoscopic Ablation System, which performs PVI using laser energy to create lines of scar tissue to block the abnormal electrical pathways that cause AFib. Using direct tissue visualization, titratable laser energy and compliant balloon technology, the HeartLight X3 System's RAPID mode leverages a precise motor control system that enables uninterrupted, high-speed, circumferential lesion creation under direct control of the physician. This results in consistently reduced procedure times.

"Our trial results using the HeartLight X3 System were outstanding, with the study meeting all the pre-specified endpoints," said Neužil. "With faster PVI and faster total ablation times combined with the already established safety and efficacy of the current HeartLight System, I anticipate that the HeartLight X3 System will be quickly adopted in the clinical setting."

The key findings of the study included:

  • HeartLight X3 procedure times were more than 90 minutes shorter than with the first-generation HeartLight System[1]; procedures can routinely be completed in one hour [2];

  • The device was able to isolate pulmonary veins in as fast as three minutes;

  • HeartLight X3 demonstrated comparable acute safety and efficacy to the first-generation HeartLight System;

  • Ninety-nine percent of pulmonary veins were isolated acutely with the device; and

  • Fluoroscopy times with HeartLight X3 were under 7 minutes per procedure, substantially lower than with the first-generation HeartLight System

The HeartLight X3 System is only approved for use in Europe. It is not available for sale in the U.S.

For more information: www.cardiofocus.com

References

1. Dukkipati SR, Cuoco F, Kutinsky I, et.al. Pulmonary Vein Isolation Using the Visually Guided Laser Balloon. JACC Vol. 66, No. 12, September 22 2015:1350-60.

2 Neužil P., Schmidt B., Chun J., et.al. Performance of a 3rd Generation Visually-Guided Laser Balloon Catheter for Pulmonary Vein Isolation: Results of the X3 Study. HRS 2019. Excluding 30 minute wait period with operators out of the learning curve.

Related Content

News | Ablation Systems

May 13, 2022 — Acutus Medical, an arrhythmia management company focused on improving the way cardiac arrhythmias are ...

Home May 13, 2022
Home
News | Ablation Systems

May 4, 2022 – Stereotaxis, the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias ...

Home May 04, 2022
Home
News | Ablation Systems

April 5, 2021 — Acutus Medical today announced initial U.S. enrollments in the company’s AcQForce Flutter ...

Home April 05, 2021
Home
News | Ablation Systems

June 16, 2020 – The Montreal Heart Institute (MHI) and Thermedical, a developer of thermal-ablation systems to treat ...

Home June 16, 2020
Home
News | Ablation Systems

May 8, 2020 – Results from a first-in-human early feasibility study (EFS) using a saline enhanced radiofrequency (SERF) ...

Home May 08, 2020
Home
Feature | Ablation Systems

May 8, 2020 — A new clinical trial effectively uses pulsed field (PF) energy to treat patients with persistent or ...

Home May 08, 2020
Home
Videos | Ablation Systems

Clifford Robinson, M.D., associate professor of radiation oncology, chief of the SBRT service, director of clinical ...

Home September 26, 2019
Home
News | Ablation Systems

September 17, 2019 — Treating high-risk heart patients with a single, high dose of radiation therapy can dramatically ...

Home September 17, 2019
Home
News | Ablation Systems

May 16, 2019 — Johnson & Johnson Medical Devices Companies announced that Biosense Webster, Inc.’s QDot Micro catheter ...

Home May 16, 2019
Home
News | Ablation Systems

May 14, 2019 — The Heart Rhythm Society (HRS) in partnership with three other professional societies issued an ...

Home May 14, 2019
Home
Subscribe Now